Clinical Trial Update: Study to Determine the Safety, Maximum Tolerated Dose, Pharmacokinetics of Sorafenib (BAY43-9006) [Phase 1]

View source ↗

Summary

Phase 1 trial of sorafenib (BAY43-9006) in carcinoma to determine safety, maximum tolerated dose, and pharmacokinetics; results were posted in 2010 after comple…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Carcinoma

Drugs mentioned

• Nexavar (Sorafenib)

Snippet

Sponsor: Bayer | Conditions: Carcinoma | Phase 1 | Status: COMPLETED | Results posted: 2010-10-08